Amyotrophic Lateral Sclerosis: Opportunity Analysis and Forecast to 2027
NEW YORK, Oct. 25, 2018 /PRNewswire/ -- Amyotrophic Lateral Sclerosis: Opportunity Analysis and Forecast to 2027
Summary
Read the full report: https://www.reportlinker.com/p05601851
Amyotrophic Lateral Sclerosis (ALS) drug sales in 2017 were approximately $187M across the seven major markets - the US, 5EU (France, Germany, Italy, Spain and the UK), and Japan. Over the 10-year forecast period, the market is expected to grow to $1.2B at a CAGR of 19.4%. This growth will be driven by the launch of six late-stage pipeline products. Currently, the highest-selling drug in the market is Mitsubishi's Radicava (edaravone).
Amyotrophic Lateral Sclerosis (ALS) is a motor neuron degenerative disease which affects both upper motor neurons (UMN) and lower motor neurons (LMN).It is a progressive disease, with patients becoming increasingly dependent on carers and physicians as time from onset increases, and ultimately, it is fatal.
ALS can be split into two origins, hereditary - which is known as FALS (Familial ALS) or idiopathic - known as SALS (sporadic ALS).
The major drivers of growth in the Amyotrophic Lateral Sclerosis (ALS) market during the forecast period include -
- The launch of five pipeline agents that aim to extend patient survival. These drugs will be used as adjunctive therapies to Rilutek and Radicava.
- The launch of BrainStorm Therapeutics' NurOwn stem cell therapy, which has the potential to significantly slow the progression of the disease and is, expected to expand the market in the future. Biologic products have a high cost of therapy and as such are expected to generate high sales.
The major barriers to growth in the Amyotrophic Lateral Sclerosis (ALS) market during the forecast period will be -
- Major brands are expected to see their patents expire throughout the forecast period, which will act as a barrier as cheap generic versions of the drug will enter the market.
- Due to the rarity of the disease, recruiting a representative patient sample for clinical trials can be difficult and may slow the clinical trial development process.
The report "Amyotrophic Lateral Sclerosis: Opportunity Analysis and Forecast to 2027", is aimed to -
- Assess the current competitive landscape and its evolution over the forecast period (2017-2027)
- Evaluate the significance of late-stage pipeline products entering the ALS market and determine how these products will impact the future treatment landscape
- Highlight the significant unmet needs in the ALS market
- Identify any opportunities in the ALS market
Companies Mentioned: Sanofi, Mitsubishi Tanabe, Brainstorm Therapeutics, ViroMed, Ionis Pharmaceuticals, Genevrone Biopharmaceuticals, Biogen, Orphazyme, Orion Pharmaceuticals, KringlePharma, Aquestive Therapeutics, Apotex, Valeant Pharmaceuticals, Neuralstem, Impicit Bioscience, Roche, Treeway BV, Cytokientics, AB Science, Concordia Healthcare Corp
Scope
- Overview of ALS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized ALS therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (familial and sporadic) forecast from 2017 to 2027.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the ALS therapeutics market
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for ALS therapy. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global ALS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global ALS therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ALS therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Read the full report: https://www.reportlinker.com/p05601851
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article